Eko Murmur Analysis Software (EMAS) vs EchoGo Amyloidosis
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 60/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Both tools are FDA-cleared AI solutions in cardiology, yet they address distinct diagnostic needs. Eko Murmur Analysis Software utilizes stethoscope data to detect and differentiate heart murmurs, providing general clinical decision support for heart and lung conditions. Conversely, Ultromics' EchoGo Amyloidosis specializes in analyzing echocardiogram video clips to aid in the early detection of cardiac amyloidosis.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
Eko Murmur Analysis Software (EMAS) is designed to detect and differentiate heart murmurs, including innocent and structural murmurs, in adult and pediatric patients, providing clinical decision support for early detection of heart and lung disease. In contrast, EchoGo Amyloidosis is an AI-powered screening tool that analyzes echocardiogram video clips to aid in the early detection of cardiac amyloidosis.
EMAS analyzes heart sound (PCG) and optional ECG data, which is acquired via integration with Eko digital stethoscopes (CORE 500, DUO, CORE). EchoGo Amyloidosis analyzes echocardiogram video clips, specifically a single apical four-chamber view, to identify suspected cardiac amyloidosis.
EMAS is a cloud-based service accessed via a mobile application, allowing for recording, playback, annotation, and saving, with PDF report generation and sharing (EHR compatible). EchoGo Amyloidosis integrates seamlessly with existing clinical workflows and IT infrastructure, including PACS, DICOM, and HL7, delivering diagnostic reports directly to PACS.
EMAS is intended for use in adult and pediatric patients for the detection and differentiation of heart murmurs. EchoGo Amyloidosis is indicated as a screening tool for adult patients aged 65 years and over with heart failure undergoing cardiovascular assessment using echocardiography, to aid in the early detection of cardiac amyloidosis.
EMAS provides clinical decision support by automatically detecting murmurs, classifying them as innocent or structural, and determining their timing and character. EchoGo Amyloidosis provides a diagnostic output of 'suggestive' or 'not suggestive' of cardiac amyloidosis based on its analysis of echocardiographic markers.
EchoGo Amyloidosis has demonstrated high diagnostic accuracy with 85% sensitivity and 93% specificity for detecting cardiac amyloidosis, and consistent performance across CA subtypes (AL, wild-type ATTR, variant ATTR). For EMAS, clinical validation studies showed 85.6% sensitivity and 84.4% specificity for significant valvular heart disease, with higher rates (90.2% sensitivity and 90.6% specificity) among adults 18 years and older for structural murmurs.